Abstract:Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, and it is essential for oncogenic transformation. Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clinical trials. Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity. Preclinical data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clinical activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer. Many optimized synthetic, small-molecule Hsp90 inhibitors from diverse chemotypes are now in clinical trials. Here, we review the discovery and development of Hsp90 inhibitors and assess their potential. There has been significant learning from studies of the basic biology of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chemical probes. Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (especially multiple myeloma) in which buffering of proteotoxic stress is critical for survival. We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.

The Hsp90 molecular chaperone: an open and shut case for treatment

Review: The HSP90 molecular chaperone—an enigmatic ATPase

HSP90 and the chaperoning of cancer

Structure, Function, and Regulation of the Hsp90 Machinery

The known unknowns of the Hsp90 chaperone

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Advances towards Understanding the Mechanism of Action of the Hsp90 Complex

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease

Structure and Mechanism of the Hsp90 Molecular Chaperone Machinery

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Establishing Order through Disorder by the Hsp90 Molecular Chaperone

Heat Shock Protein 90 in Neurodegenerative Diseases

Heat Shock Protein 90 Inhibitors: an Update on Achievements, Challenges, and Future Directions.

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer

The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones

Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?